Chronic pain is exhausting. It wears people down physically, emotionally, financially and socially. So when someone hears “THC” or “CBD” might help, the question is usually not philosophical. It’s personal. But here’s the hard part: cannabis is marketed like a sure thing, while the science is still catching up.
A major updated systematic review published in late 2025 pulled together randomized, placebo controlled trials on cannabis-based products for chronic pain. It’s one of the cleanest ways to answer the question, “What does the best evidence actually say right now?”
This article breaks down what the research shows in 2026, in plain English, with the tradeoffs stated out loud.
Why this topic matters right now
More people are trying cannabis for pain than ever and they’re doing it across every setting: medical programs, adult use markets, and hemp derived product channels. At the same time, most consumers do not get a real evidence-based conversation before they try something.
That creates two common problems:
- People expect a big result and get a modest one
- People chase the benefit upward and run into side effects
If you’re going to talk about cannabis for chronic pain responsibly, you must talk about both.
The study this 2026 update is based on
The review was published Dec 23, 2025 in Annals of Internal Medicine and focused on randomized clinical trials, which are the most useful type of study for answering “does it work?” questions.
Key details (because they matter):
• 25 clinical trials, totaling 2,303 adults with chronic pain
• Most participants had neuropathic pain (nerve pain), so the evidence leans heavily in that direction
• Trials were short term, about 1 to 6 months, meaning we still have limited long term clarity
• Products were grouped by THC:CBD ratio and delivery method, because those differences change both outcomes and side effects
What “slight pain reduction” really means
The most honest takeaway from this evidence is simple:
Some THC containing products can reduce pain a little, for some people, in the short term. And side effects become more likely as THC exposure rises. That word “slight” matters. In research, a small average improvement can still be meaningful for an individual person.
But it is not the same thing as “this will fix your pain,” and it doesn’t guarantee better function, better mobility or a better day to day life. So the best framing is not “Does cannabis work for pain?” It’s “Is the benefit big enough for you to justify the tradeoffs and how will you measure that?”
What products showed the clearest benefit signal
The review found the most consistent benefit signal in products with higher THC relative to CBD and in products with comparable THC to CBD ratios, depending on formulation and route.
Put plainly:
• Higher THC products: more likely to show short term pain improvement, but more side effects
• CBD dominant or CBD only products: did not show clear pain improvement in these randomized trials
This is one of the most important points for public education right now because it runs directly against a lot of marketing.
THC only products are not all the same
A detail most people miss is that “THC” is not a single uniform experience across products and formulations.
The review’s pooled results differed by THC based medications in the trials, which is a reminder that the compound, the formulation, and the dosing pattern all shape real world outcomes. If you’re educating consumers or clinicians, this is a key lesson:
“THC helped” is not a precise statement.
“What form, what ratio, what route, what duration, and what outcomes?” is where the truth lives.
What about low THC products and CBD alone
This is the part many people want to be true, because CBD feels safer and more accessible.
But in the randomized trial evidence summarized here, CBD only formulations showed little to no improvement in chronic pain outcomes. That does not mean CBD has no value for anyone, for any symptom, ever. It does mean you should be cautious about promising CBD as a reliable standalone solution for chronic pain.
If your mission is trust, this is where you earn it: say what the evidence says, even when it disappoints expectations.
Side effects and tradeoffs: where risk shows up
The trials found increased risk of common adverse effects with THC containing products, including symptoms such as dizziness, sedation and nausea.
That doesn’t mean “don’t use THC.” It means:
• Plan for side effects
• Start lower than you think you need
• Build a structure for decision making rather than guessing
This is especially important for people who are older, prone to falls, sensitive to sedation or doing safety sensitive work.
Who might be more likely to benefit
Because the trials skewed toward neuropathic pain, the most defensible statement is:
The evidence signal is strongest in nerve pain populations and weaker or less clear in other chronic pain types. If someone has musculoskeletal pain, inflammatory pain, mixed pain, trauma related pain, or complex pain syndromes, the evidence is not as direct. That doesn’t mean “no benefit.” It means the confidence level is lower.
A realistic “if you try it” framework
This is not medical advice. It’s a practical way to think. Before you try cannabis for chronic pain, define these three things:
- Your target outcome
Examples: pain severity, sleep quality, daily function, fewer flare days - Your success threshold. What change would make it worth it?
- Your stop rule. What side effects or downsides mean it’s not a fit?
Then keep it simple:
• Start low and go slow
• Change one variable at a time (product, ratio, dose, timing)
• Track results for 2 to 4 weeks in a basic log
• Avoid mixing with other sedatives unless you have clinician guidance
• Reevaluate honestly: “Is this helping enough to justify it?”
What we still need research to answer
Even with a strong review, the gaps remain real:
• Longer term trials beyond a few months
• Standardized products with consistent labeling and verified composition
• Better evidence across different pain conditions, not mostly neuropathic pain
• Outcomes that reflect real life: function, sleep, quality of life, and medication reduction
Bottom line
In 2026, the best randomized trial evidence suggests this:
THC containing cannabis products may provide small, short term improvements in chronic pain, especially nerve pain, but they also increase common side effects like dizziness, sedation and nausea. CBD only products do not show clear pain benefit in these trials.
If you’re going to use cannabis for pain, do it with clear expectations, clear tracking and real respect for the tradeoffs.
If you want cannabis education that is evidence led, practical, and honest, keep learning with Herbal IQ Education. We translate new research into clear takeaways for consumers, clinicians, retailers, and policymakers, without hype and without fear. Follow along here and on LinkedIn, and if you have a topic you want us to break down next, send it our way.
Cited Information
Roger Chou, Rongwei Fu, Azrah Y. Ahmed, et al. Cannabis-Based Products for Chronic Pain: An Updated Systematic Review. Ann Intern Med. [Epub 23 December 2025]. doi:10.7326/ANNALS-25-03152
